Point-of-Care Testing (POCT) Market Size, Share, Growth Analysis, By Product Type(Covid -19 testing kits, Glucose monitoring products, Meters, Strips), By Platform(Lateral Flow Assays, Dipsticks, Microfluids, Molecular Diagnostics), By Mode of Purchase(OTC products, Prescribed based products), By Testing Type(Immunoassays, Cell-Based Assays, Nucleic Acid Amplification Testing, Clinical Chemistry Assays), By End-User(Clinical laboratories, Ambulatory care facilities and physician offices, Pharmacies, retail clinics & E-comm platforms), By Geography(North America, Europe, Asia-Pacific, Latin America) - Industry Forecast 2025-2032

The market for Point-of-Care Testing (POCT) was estimated to be valued at US$ XX Mn in 2021.

The Point-of-Care Testing (POCT) Market is estimated to grow at a CAGR of XX% by 2028.

The Point-of-Care Testing (POCT) Market is segmented on the basis of Product Type, Platform, Mode of Purchase, Testing Type, End-User, Geography.

Based on region, the Point-of-Care Testing (POCT) Market is segmented into North America, Europe, Asia Pacific, Middle East & Africa and Latin America.

The key players operating in the Point-of-Care Testing (POCT) Market are , Sinocare Inc , Hoffmann La Roche Ltd , Siemens AG , Abott Laboratories , bioMrieux SA , Becton Dickinson and Company, Danaher Coraporation, Nova Biomedical, Sysmex corporation, Johnson and Johnson, Biosensor Inc, Fluxergy, Precision, Ascensia Diabetes Care Holding AG, LifeScan IP Holdings, LLC , Mankind pharma , OraSure Technologies, inc , A. Menarini Diagnostics s.r.l , ACON Laboratories , Trinity Biotech plc.